Opinion|Videos|December 23, 2024
Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
Advertisement
Video content above is prompted by the following:
- What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
- How will this abstract affect your clinical decision-making?
- The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
- What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
- How do these results influence your clinical practice?
- How do you see the GVHD treatment landscape changing with the introduction of axatilimab?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Investigating the Role of Gut Microbiota in IPF
2
Cost, Access Barriers Limit Women’s Use of Heart Monitors: Lindsey Valenzuela, PharmD
3
GLP-1s Support Weight Loss, Symptom Relief in Psoriasis, Hidradenitis Suppurativa
4
Frequent Dining Out Linked to Higher Colorectal Cancer Risk
5
